- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07568626
Factors for Prolonged Hospital Stays in Patients Undergoing ERCP
13. juli 2026 oppdatert av: Yanglin Pan, Air Force Military Medical University, China
Factors Associated With Prolonged Hospital Stay in Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Prospective, Multicenter Cohort Study
Endoscopic retrograde cholangiopancreatography (ERCP) is a crucial minimally invasive technique for the diagnosis and treatment of biliary and pancreatic diseases.
However, it remains technically demanding and carries a postoperative adverse event (AE) rate exceeding 10% (e.g., pancreatitis, bleeding, and perforation), which subsequently leads to prolonged length of stay (LOS) and increased healthcare costs.
With the rapid acceleration of population aging, the clinical demand for ERCP among the elderly has surged.
Although ERCP is generally considered safe for older adults, advanced age also increases the risk of ERCP-related AEs and prolonged LOS.
While previous studies investigated the outcomes of ERCP in elderly patients, those studies were predominantly retrospective, accompanied by selection bias.
Moreover, insufficient factors were included in those retrospective studies.
Importantly, some aging-related parameters, such as frailty, functional reserve, cognitive and psychological status, were not included in previous studies.
Therefore, the investigators conducted a prospective, multicenter cohort study aimed at investigating outcomes in elderly patients undergoing ERCP and comprehensive factors (patient-related, procedure-related, and geriatric factors) associated with adverse outcomes.
Studieoversikt
Status
Rekruttering
Studietype
Observasjonsmessig
Registrering (Antatt)
504
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Yanglin Pan, M.D
- Telefonnummer: 13991811225
- E-post: yanglinpan@hotmail.com
Studiesteder
-
-
Fujian
-
Xiamen, Fujian, Kina, 361009
- Rekruttering
- Xiamen Hong'ai Hospital
-
Ta kontakt med:
- Rongchun Zhang, M.D
- Telefonnummer: 15829395908
- E-post: zrc.700502@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710000
- Rekruttering
- Xijing Hospital of Digestive Diseases
-
Ta kontakt med:
- Yanglin Pan, M.D
- Telefonnummer: 13991811225
- E-post: yanglinpan@hotmail.com
-
Xi'an, Shaanxi, Kina, 710054
- Rekruttering
- Department of Gastroenterology, 986 Hospital of Xijing Hospital, Fourth MilitaryMedical University
-
Ta kontakt med:
- Jun Wang, M.D
- Telefonnummer: 86-29-84734201
- E-post: Wangjundoctor@aliyun.com
-
Xi'an, Shaanxi, Kina, 710038
- Rekruttering
- The Second Affiliated Hospital of Air Force Military Medical University
-
Ta kontakt med:
- Zhenxiong Liu, M.D
- Telefonnummer: 13572276166
- E-post: liuzhx816@126.com
-
Xi'an, Shaanxi, Kina, 710054
- Rekruttering
- Xi'an Honghui Hospital
-
Ta kontakt med:
- Yupeng Shi, M.M
- Telefonnummer: 13891893748
- E-post: xjshiyupeng@163.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Patients aged ≥ 65 years old who are scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) are eligible for our study.
Beskrivelse
Inclusion Criteria:
- Patient age ≥ 65 years
- Scheduled to undergo ERCP procedure
Exclusion Criteria:
- Severe cognitive dysfunction
- Severe hearing impairment
- Known or suspected gastrointestinal perforation
- Hemodynamic instability
- Pregnant or lactating women
- Unable to sign the informed consent form
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Prolonged Postoperative Length of Stay
Tidsramme: 30 days
|
A binary outcome defined as a postoperative length of stay > 5 days.
It is calculated as the duration from the completion of the ERCP procedure to the date of formal hospital discharge.
|
30 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of total adverse events
Tidsramme: 30 days
|
Adverse events include ERCP-related or non ERCP-related adverse events
|
30 days
|
|
Total Length of Hospital Stay
Tidsramme: 30 days
|
Total length of stay (TLOS), defined as the total duration in days from the date of hospital admission to the date of hospital discharge.
|
30 days
|
|
Post-procedure Length of Hospital Stay
Tidsramme: 30 days
|
The number of days from the day of the ERCP procedure to hospital discharge
|
30 days
|
|
Rate of post-ERCP Pancreatitis
Tidsramme: 30 days
|
a new or aggravated upper abdominal pain, with an elevated pancreatic enzyme of at least 3 times as the upper limit of normal value 24h after procedure and prolonged hospitalization days for at least 2 days.
This definition was based on a widely recognized Cotton consensus.
|
30 days
|
|
Rate of ERCP-related bleeding
Tidsramme: 30 days
|
Bleeding was established according to Cotton criteria.
Mild: a documented decrease in hemoglobin concentration by <3 g/L, without requiring the blood transfusion; Moderate: blood transfusion ≤ 4 units; without need for angiographic or surgery interventions ;Severe: Transfusion: ≥ 5 units or requiring for angiographic or surgery interventions.
|
30 days
|
|
Rate of ERCP-related perforation
Tidsramme: 30 days
|
Perforation was established according to Cotton criteria.Mild: slight leakage of fluid or contrast dye, manageable through fluid administration and suction therapy 3 days; Moderate: definite perforation required to be managed for 4-10 days; Severe: management for more than 10 days or requiring for percutaneous or surgical intervention.
|
30 days
|
|
Rate of ERCP-related infection
Tidsramme: 30 days
|
Infection was established according to Cotton criteria.Mild: temperature >38℃ for 24-48h; Moderate: Febrile illness requiring >3 days of hospital treatment; endoscopic or percutaneous interventions; Severe: septic shock or requiring surgery.
|
30 days
|
|
Total Hospitalization Costs
Tidsramme: 30 days
|
The sum of all medical expenses incurred during the entire hospitalization, denominated in Chinese Yuan (CNY).
This includes costs for medication, laboratory and imaging tests, treatments, procedures, surgical operations, medical supplies, and bed occupancy.
|
30 days
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
15. februar 2026
Primær fullføring (Antatt)
1. januar 2027
Studiet fullført (Antatt)
1. januar 2027
Datoer for studieregistrering
Først innsendt
28. april 2026
Først innsendt som oppfylte QC-kriteriene
28. april 2026
Først lagt ut (Faktiske)
6. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
14. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- KY20252608-C-1
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .